Long-Term Safety of “4-Hour” Hemoadsorption Combined with Hemodialysis in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study
Blood Purification · 2025
DOI: 10.1159/000545988 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Blood Purification, 2025. Verfasst von Dongliang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Beijing Jishuitan Hospital affiliated to Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Renal Dialysis, Kidney Failure, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Current guidelines recommend limiting hemoadsorption (HA) duration to 2 h during hemodialysis (HD) sessions due to theoretical concerns about adsorbent saturation and clotting risks. This multicenter prospective cohort study evaluated the long-term safety and efficacy of a novel “4Hs” protocol (4-h HA-HD with blood flow >250 mL/min).
Methods
78 maintenance HD patients from four centers underwent 26 weeks of 4Hs therapy. Key outcomes included dialysis adequacy (spKt/V, urea reduction ratio [URR]), uremic toxin (UT) clearance (indoxyl sulfate [IS], p-cresyl sulfate, β2 microglobulin [B2MG]), clotting rates, and adverse events. Statistical comparisons were made against pre-study conventional HA+HD (2-h HA) data using paired t-tests and repeated-measures ANOVA.
Results
The 4Hs protocol demonstrated non-inferior safety to conventional HA+HD, with comparable clotting rates (1.79% vs. 1.62%, p = 0.665) and no significant differences in anemia markers or hypoalbuminemia. Dialysis efficacy improved significantly: spKt/V increased by 0.28 (p = 0.012), URR by 1.18% (p = 0.003), and UT reduction rates (IS: 56.17% vs. 40.14%, p < 0.001; pCS: 47.39% vs. 35.91%, p < 0.001; B2MG: 55.82% vs. 48.41%, p < 0.001). Albumin loss remained comparable between protocols (Δ 0.5 g/L, p > 0.05).
Conclusion
Extending HA duration to 4 h with high-flow hemodynamics (Qb >250 mL/min) is safe and enhances toxin clearance without increasing clotting risks. These findings challenge current SOP limitations on HA duration and support protocol optimization in maintenance HD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department, Beijing Jishuitan Hospital affiliated to Capital Medical University, Beijing, China.
- Nephrology Department, Beijing Geriatric Hospital, Beijing, China.
- Nephrology Rehabilitation Center, Beijing Zhongguancun Hospital, Beijing, China.
- Nephrology Department, Beijing Changping Hospital of Integrated Chinese and Western Medicine, Beijing, China.
Zitieren
APA
Zhang, D., Liu, C., Yang, T., Zhao, J., Wang, X., Zhang, L., Li, Y., Shen, Y., Gao, Y., Zhang, H., & Zhang, D. (2025). Long-Term Safety of “4-Hour” Hemoadsorption Combined with Hemodialysis in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study. Blood Purification. https://doi.org/10.1159/000545988
Vancouver
Zhang D, Liu C, Yang T, Zhao J, Wang X, Zhang L, et al. Long-Term Safety of “4-Hour” Hemoadsorption Combined with Hemodialysis in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study. Blood Purification. 2025. doi:10.1159/000545988
BibTeX
@article{Zhang2025,
author = {Zhang, Dongliang and Liu, Cuiping and Yang, Tao and Zhao, Jingxin and Wang, Xiaofei and Zhang, Liping and Li, Yuanyuan and Shen, Yangyang and Gao, Yanjun and Zhang, Hongjuan and Zhang, Dongliang},
title = {Long-Term Safety of “4-Hour” Hemoadsorption Combined with Hemodialysis in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study},
journal = {Blood Purification},
year = {2025},
doi = {10.1159/000545988}
}
EUVIMED